跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
mRNA therapeutics
首页
药物
mRNA therapeutics
mRNA therapeutics
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
METHODS FOR THERAPEUTIC ADMINISTRATION OF MESSENGER RIBONUCLEIC ACID DRUGS
EP 3359670 B2
申请人: MODERNATX INC
优先权: 2015
EP
US
WO
8 件公开
DEUTERIUM-STABILISED RIBONUCLEIC ACID (RNA) MOLECULES DISPLAYING INCREASED RESISTANCE TO THERMAL AND ENZYMATIC HYDROLYSIS, AQUEOUS COMPOSITIONS COMPRISING STABILIZED RNA MOLECULES AND METHODS FOR MAKING SAME
EP 4244351 A4
申请人: DEUTRAMED SOLUTIONS LTD
优先权: 2020
EP
US
WO
5 件公开
MODULAR LIPID COMPOUNDS AND TWO- TO THREE-COMPONENT LIPID NANOPARTICLE COMPOSITIONS
EP 4642787 A2
申请人: SUNVAX MRNA THERAPEUTICS
优先权: 2022
EP
US
WO
5 件公开
Modular targeted therapeutic agents and methods of making same
US 10206998 B2
申请人: PROTEONOVA INC
优先权: 2013
US
5 件公开
IN VIVO TARGETING OF T CELLS FOR MRNA THERAPEUTICS
EP 4228602 A4
申请人: UNIV PENNSYLVANIA
优先权: 2020
CN
EP
US
WO
4 件公开
IN VIVO TARGETING OF CD4+ -T CELLS FOR MRNA THERAPEUTICS
EP 4259105 A1
申请人: UNIV PENNSYLVANIA
优先权: 2020
EP
US
WO
4 件公开
IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
EP 4504711 A2
申请人: SUNVAX MRNA THERAPEUTICS INC
优先权: 2022
EP
US
WO
4 件公开
NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE
EP 3263717 A1
申请人: MOLECULAR HEALTH GMBH
优先权: 2009
EP
US
4 件公开
Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CN 104685056 A
申请人: MIRAGEN THERAPEUTICS
优先权: 2013
CN
US
4 件公开
IONIZABLE LIPIDS AND METHODS OF MANUFACTURE AND USE THEREOF
US 2022218622 A1
申请人: GEORGE MASON RES FOUNDATION INC
优先权: 2020
US
WO
4 件公开
第 1 / 7 页
上一页
下一页
药物
反馈